Company: WHWK
Filing Date: 2025-05-13
Form Type: CORRESP
Source: 0001193125-25-119011
Chunk: 1

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-13
Form: CORRESP
Chunk 1
---
 29
of its Quarterly Report on Form 10-Q, filed on May 8, 2025, as follows:

“WuXi Biologics License Agreement

On December 19, 2024, we entered into the License Agreement with WuXi Biologics for exclusive
rights to certain patents and know-how pertaining to WuXi Biologics’ preclinical ADC Therapies leveraging Hangzhou DAC linker-payload technology targeting each of MUC16, PTK7 and SEZ6. Under the License
Agreement, we paid WuXi Biologics a non-refundable, partial upfront payment of $6.0 million on December 19, 2024 and we paid an additional non-refundable,
upfront payment of $38.0 million on April 16, 2025, in each case, for the rights and licenses granted to us by WuXi Biologics. In accordance with the License Agreement, WuXi Biologics is eligible to receive from us (a)up to an aggregate of $265.0million upon the achievement of certain development milestones, and (b)up to an aggregate of $540.0million upon the achievement of certain commercial milestones, across all ADC Therapies programs. WuXi Biologics is also entitled to running royalties ranging from low-single-digitto upper-single-digit percentages of annual net sales of licensed products in the territory on a product-byproduct and region-by-regionbasis from the first commercial sale of the applicable licensed product in a particular region until the date which is the later of (i)expiration of the last to expire valid claim of a license patent in such region covering the sale of such licensed product in such region or (ii)ten years after the first commercial sale of such licensed product in such region.

Each party may terminate the License Agreement in its entirety, or on a program-by-programbasis, as applicable, if the other party remains in material breach of the License Agreement following a cure period to remedy the material breach or if the other party is declared insolvent or in similar financial distress. In addition, WuXi Biologics may terminate the License Agreement on a program-by-programbasis if we do not meet certain development due diligence milestones. We may terminate the License Agreement in its entirety, or on a program-by-programbasis, as applicable, with or without cause.”

The Company also confirms that in future filings, wherever the Company discloses the material terms of the License Agreement with WuXi
Biologics, the Company